Conditions: Hepatitis C, Chronic
Keywords: Thrombocytopenia Hepatitis C, chronic
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 45
Healthy volunteers: no

Brief summary:
The purpose of this study is to assess the ability of SB-497115-GR to raise platelet counts in thrombocytopenic patients with hepatitis C virus (HCV) infection (platelet count \<80,000 /μL, suggestive of compensated cirrhosis) to a level desirable to initiate antiviral therapy and to assess the ability of SB-497115-GR to maintain platelet counts at a level sufficient to minimise dose reductions of pegylated interferon (Peg-IFN) and ribavirin (RBV) therapy with the expectation that a lower rate of Peg-IFN dose reduction and omission will translate to a higher rate of sustained viral response.

Detailed description:

Arms:
arm 1: investigational product for thrombocytopenia

Interventions: intervention 1: SB-497115-GR
Intervention descriptions: intervention 1: TPO receptor agonist to increase platelet count

Protocol document: